MedTrace Logo

Study of the Effect of the ROX AC1 on Exercise Capacity and Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00832611 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2015-01-29

No results posted yet for this study

Summary

To demonstrate the efficacy of ROX AC1 (with respect to exercise capacity and quality of life) in patients with COPD.

Conditions

Interventions

DEVICE

Arteriovenous Fistula (ROX AC1)

The percutaneous creation of an arteriovenous fistula.

Sponsors & Collaborators

  • ROX Medical, Inc.

    lead INDUSTRY

Principal Investigators

  • Claus Vogelmeier, MD · Universitätsklinikum Gieβen und Marburg, Standort Marburg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2011-03-31
Completion
2011-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00832611 on ClinicalTrials.gov